Deerfield Management Company, L.P. (Series C) Delcath Systems, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.76 Billion
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$3.1 - $4.8 $43,189 - $66,873	-13,932 Reduced 2.79%	486,068 $1.56 Million
Q4 2020 Feb 16, 2021	BUY	$10.55 - $18.69 $5.28 Million - $9.35 Million	500,000 New	500,000 $8.96 Million

Others Institutions Holding DCTH

# of Institutions

Shares Held

7.93M

Call Options Held

118K

Put Options Held

69.9K

Aigh Capital Management LLC Baltimore, MD

2.4M
Shares

$24.9 Million
7.28% of portfolio
Vivo Capital, LLC Palo Alto, CA

1.67M
Shares

$17.3 Million
2.06% of portfolio
Vanguard Group Inc Valley Forge, PA

996K
Shares

$10.3 Million
0.0% of portfolio
Essex Investment Management CO LLC Boston, MA

337K
Shares

$3.49 Million
0.57% of portfolio
Geode Capital Management, LLC Boston, MA

245K
Shares

$2.53 Million
0.0% of portfolio

View Full List

About DELCATH SYSTEMS, INC.

Ticker DCTH
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 8,597,680
Market Cap $89.1M
Description
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...

More about DCTH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account